Patient-derived tumor xenografts are susceptible to formation of human lymphocytic tumors

Gennadiy Bondarenko, Andrey Ugolkov, Stephen Rohan, Piotr Kulesza, Oleksii Dubrovskyi, Demirkan Gursel, Jeremy Mathews, Thomas V. O'Halloran, Jian J. Wei, Andrew P. Mazar*

*Corresponding author for this work

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Patient-derived xenograft (PDX) tumor models have emerged as a new approach to evaluate the effects of cancer drugs on patients' personalized tumor grafts enabling to select the best treatment for the cancer patient and providing a new tool for oncology drug developers. Here, we report that human tumors engrafted in immunodeficient mice are susceptible to formation of B-and T-cell PDX tumors.We xenografted human primary and metastatic tumor samples into immunodeficient mice and found that a fraction of PDX tumors generated from patients' samples of breast, colon, pancreatic, bladder and renal cancer were histologically similar to lymphocytic neoplasms.Moreover, we found that the first passage of breast and pancreatic cancer PDX tumors after initial transplantation of the tumor pieces from the same human tumor graft could grow as a lymphocytic tumor in one mouse and as an adenocarcinoma in another mouse. Whereas subcutaneous PDX tumors resembling human adenocarcinoma histology were slow growing and non-metastatic, we found that subcutaneous PDX lymphocytic tumors were fast growing and formed large metastatic lesions in mouse lymph nodes, liver, lungs, and spleen. PDX lymphocytic tumors were comprised of B-cells which were Epstein-Barr virus positive and expressed CD45 and CD20. Because B-cells are typically present in malignant solid tumors, formation of B-cell tumor may evolve in a wide range of PDX tumor models.Although PDX tumor models show great promise in the development of personalized therapy for cancer patients, our results suggest that confidence in any given PDX tumor model requires careful screening of lymphocytic markers.

Original languageEnglish (US)
Pages (from-to)735-741
Number of pages7
JournalNeoplasia
Volume17
Issue number9
DOIs
StatePublished - Jan 1 2015

Fingerprint

Heterografts
Neoplasms
B-Lymphocytes
Pancreatic Neoplasms
Adenocarcinoma
Breast Neoplasms
Transplants
Kidney Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Medicine(all)

Cite this

Bondarenko, G., Ugolkov, A., Rohan, S., Kulesza, P., Dubrovskyi, O., Gursel, D., ... Mazar, A. P. (2015). Patient-derived tumor xenografts are susceptible to formation of human lymphocytic tumors. Neoplasia, 17(9), 735-741. https://doi.org/10.1016/j.neo.2015.09.004
Bondarenko, Gennadiy ; Ugolkov, Andrey ; Rohan, Stephen ; Kulesza, Piotr ; Dubrovskyi, Oleksii ; Gursel, Demirkan ; Mathews, Jeremy ; O'Halloran, Thomas V. ; Wei, Jian J. ; Mazar, Andrew P. / Patient-derived tumor xenografts are susceptible to formation of human lymphocytic tumors. In: Neoplasia. 2015 ; Vol. 17, No. 9. pp. 735-741.
@article{96e0a9e68b83433aa68bc706636db06d,
title = "Patient-derived tumor xenografts are susceptible to formation of human lymphocytic tumors",
abstract = "Patient-derived xenograft (PDX) tumor models have emerged as a new approach to evaluate the effects of cancer drugs on patients' personalized tumor grafts enabling to select the best treatment for the cancer patient and providing a new tool for oncology drug developers. Here, we report that human tumors engrafted in immunodeficient mice are susceptible to formation of B-and T-cell PDX tumors.We xenografted human primary and metastatic tumor samples into immunodeficient mice and found that a fraction of PDX tumors generated from patients' samples of breast, colon, pancreatic, bladder and renal cancer were histologically similar to lymphocytic neoplasms.Moreover, we found that the first passage of breast and pancreatic cancer PDX tumors after initial transplantation of the tumor pieces from the same human tumor graft could grow as a lymphocytic tumor in one mouse and as an adenocarcinoma in another mouse. Whereas subcutaneous PDX tumors resembling human adenocarcinoma histology were slow growing and non-metastatic, we found that subcutaneous PDX lymphocytic tumors were fast growing and formed large metastatic lesions in mouse lymph nodes, liver, lungs, and spleen. PDX lymphocytic tumors were comprised of B-cells which were Epstein-Barr virus positive and expressed CD45 and CD20. Because B-cells are typically present in malignant solid tumors, formation of B-cell tumor may evolve in a wide range of PDX tumor models.Although PDX tumor models show great promise in the development of personalized therapy for cancer patients, our results suggest that confidence in any given PDX tumor model requires careful screening of lymphocytic markers.",
author = "Gennadiy Bondarenko and Andrey Ugolkov and Stephen Rohan and Piotr Kulesza and Oleksii Dubrovskyi and Demirkan Gursel and Jeremy Mathews and O'Halloran, {Thomas V.} and Wei, {Jian J.} and Mazar, {Andrew P.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.neo.2015.09.004",
language = "English (US)",
volume = "17",
pages = "735--741",
journal = "Neoplasia",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "9",

}

Bondarenko, G, Ugolkov, A, Rohan, S, Kulesza, P, Dubrovskyi, O, Gursel, D, Mathews, J, O'Halloran, TV, Wei, JJ & Mazar, AP 2015, 'Patient-derived tumor xenografts are susceptible to formation of human lymphocytic tumors', Neoplasia, vol. 17, no. 9, pp. 735-741. https://doi.org/10.1016/j.neo.2015.09.004

Patient-derived tumor xenografts are susceptible to formation of human lymphocytic tumors. / Bondarenko, Gennadiy; Ugolkov, Andrey; Rohan, Stephen; Kulesza, Piotr; Dubrovskyi, Oleksii; Gursel, Demirkan; Mathews, Jeremy; O'Halloran, Thomas V.; Wei, Jian J.; Mazar, Andrew P.

In: Neoplasia, Vol. 17, No. 9, 01.01.2015, p. 735-741.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Patient-derived tumor xenografts are susceptible to formation of human lymphocytic tumors

AU - Bondarenko, Gennadiy

AU - Ugolkov, Andrey

AU - Rohan, Stephen

AU - Kulesza, Piotr

AU - Dubrovskyi, Oleksii

AU - Gursel, Demirkan

AU - Mathews, Jeremy

AU - O'Halloran, Thomas V.

AU - Wei, Jian J.

AU - Mazar, Andrew P.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Patient-derived xenograft (PDX) tumor models have emerged as a new approach to evaluate the effects of cancer drugs on patients' personalized tumor grafts enabling to select the best treatment for the cancer patient and providing a new tool for oncology drug developers. Here, we report that human tumors engrafted in immunodeficient mice are susceptible to formation of B-and T-cell PDX tumors.We xenografted human primary and metastatic tumor samples into immunodeficient mice and found that a fraction of PDX tumors generated from patients' samples of breast, colon, pancreatic, bladder and renal cancer were histologically similar to lymphocytic neoplasms.Moreover, we found that the first passage of breast and pancreatic cancer PDX tumors after initial transplantation of the tumor pieces from the same human tumor graft could grow as a lymphocytic tumor in one mouse and as an adenocarcinoma in another mouse. Whereas subcutaneous PDX tumors resembling human adenocarcinoma histology were slow growing and non-metastatic, we found that subcutaneous PDX lymphocytic tumors were fast growing and formed large metastatic lesions in mouse lymph nodes, liver, lungs, and spleen. PDX lymphocytic tumors were comprised of B-cells which were Epstein-Barr virus positive and expressed CD45 and CD20. Because B-cells are typically present in malignant solid tumors, formation of B-cell tumor may evolve in a wide range of PDX tumor models.Although PDX tumor models show great promise in the development of personalized therapy for cancer patients, our results suggest that confidence in any given PDX tumor model requires careful screening of lymphocytic markers.

AB - Patient-derived xenograft (PDX) tumor models have emerged as a new approach to evaluate the effects of cancer drugs on patients' personalized tumor grafts enabling to select the best treatment for the cancer patient and providing a new tool for oncology drug developers. Here, we report that human tumors engrafted in immunodeficient mice are susceptible to formation of B-and T-cell PDX tumors.We xenografted human primary and metastatic tumor samples into immunodeficient mice and found that a fraction of PDX tumors generated from patients' samples of breast, colon, pancreatic, bladder and renal cancer were histologically similar to lymphocytic neoplasms.Moreover, we found that the first passage of breast and pancreatic cancer PDX tumors after initial transplantation of the tumor pieces from the same human tumor graft could grow as a lymphocytic tumor in one mouse and as an adenocarcinoma in another mouse. Whereas subcutaneous PDX tumors resembling human adenocarcinoma histology were slow growing and non-metastatic, we found that subcutaneous PDX lymphocytic tumors were fast growing and formed large metastatic lesions in mouse lymph nodes, liver, lungs, and spleen. PDX lymphocytic tumors were comprised of B-cells which were Epstein-Barr virus positive and expressed CD45 and CD20. Because B-cells are typically present in malignant solid tumors, formation of B-cell tumor may evolve in a wide range of PDX tumor models.Although PDX tumor models show great promise in the development of personalized therapy for cancer patients, our results suggest that confidence in any given PDX tumor model requires careful screening of lymphocytic markers.

UR - http://www.scopus.com/inward/record.url?scp=84948992756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948992756&partnerID=8YFLogxK

U2 - 10.1016/j.neo.2015.09.004

DO - 10.1016/j.neo.2015.09.004

M3 - Article

VL - 17

SP - 735

EP - 741

JO - Neoplasia

JF - Neoplasia

SN - 1522-8002

IS - 9

ER -